Table 5.11Incremental costs and effectiveness by treatment strategy for solid tumour patients who can take quinolone (baseline risk of neutropenic sepsis of one course of chemotherapy: 34.41%)

StrategyTotal costs (£)Total QALYsIncremental costs (£)Incremental QALYsICER (£) versus baseline (QALYs)ICER (£) incremental (QALYs)
Primary prophylaxis with quinolone£270.4-8.9*10-4——ComparatorComparator
Secondary prophylaxis with quinolone£423.7-1.9*10-3£153.3-1.0*10-3DominatedDominated
Nothing/Placebo£473.9-2.3*10-3£203.5-1.4*10-3DominatedDominated
Secondary prophylaxis with PEG-G-CSF£773.6-1.8*10-3£503.2-8.9*10-4DominatedDominated
Primary prophylaxis with PEG-G-CSF£2170.2-5.6*10-4£1,899.83.3*10-4£5.7 million£5.7 million

From: 5, Reducing the risk of septic complications of anticancer treatment

Cover of Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
NICE Clinical Guidelines, No. 151.
National Collaborating Centre for Cancer (UK).
Copyright © National Collaborating Centre for Cancer, 2012.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.